(NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Shanta Chawla, M.D. as Vice President, Clinical Development. Dr. Chawla has more than 13 years of clinical research, operations and development experience, with a focus on oncology therapeutics.
“In this new position, Dr. Chawla will play a key role in the management of our upcoming global Phase 3 clinical trial under a Special Protocol Assessment with aldoxorubicin as a second-line treatment for soft tissue sarcomas,” said CytRx Executive Vice President and Chief Medical Officer Dr. Daniel Levitt. “She has designed and managed large clinical trials in North America and Europe for a range of cancer types, and brings to CytRx a proven ability to meet enrollment targets and work within budget requirements. We are fortunate to have Dr. Chawla join our team as we move into a very exciting and demanding phase of activity.”
“I am delighted to be joining CytRx at this critical point in the company’s development, and in particular in light of the recently announced highly positive results from the global Phase 2b trial with aldoxorubicin in advanced soft tissue sarcomas,” said Dr. Chawla. “I look forward to playing a significant role in the continued development of this promising oncology therapeutic.”
From 2001 to 2013 Dr. Chawla was at Spectrum Pharmaceuticals, most recently as Vice President, Clinical Research and Development, where her expertise included selecting clinical trial sites and principal investigators, establishing protocols with the FDA and key opinion leaders, preparing FDA filings and project team management. Dr. Chawla received her M.D. from Maulana Azad Medical College in New Delhi, and performed her internship and residency in Philadelphia at Albert Einstein Medical Center and Thomas Jefferson University Hospital, respectively. She is board certified in Internal Medicine. Dr. Shanta Chawla is not related to Dr. Sant Chawla, the principal investigator in CytRx’s global Phase 3 clinical trial for soft tissue sarcoma.